Ziconotide for the treatment of severe spasticity after spinal cord injury.
Spasticity is a major clinical manifestation of spinal cord injury and upper motor neuron syndrome.
Ridgeway
B
B
Department of Anesthesiology, University of California, San Diego, 9500 Gilman Drive 0924, La Jolla, USA.
Wallace
M
M
Gerayli
A
A
D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use; D001418:Baclofen / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D009020:Morphine / Q000627:therapeutic use; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D010264:Paraplegia / Q000150:complications; D011782:Quadriplegia / Q000150:complications; D013119:Spinal Cord Injuries / Q000150:complications*; D020960:omega-Conotoxins / Q000627:therapeutic use*
D000701:Analgesics, Opioid; D002121:Calcium Channel Blockers; D009125:Muscle Relaxants, Central; D020960:omega-Conotoxins; D009020:Morphine; C078452:ziconotide; D001418:Baclofen